NYSE:PFEPharmaceuticals
Pfizer Novavax Matrix M Deal Adds New Angle To Vaccine Story
Pfizer (NYSE:PFE) has entered a non exclusive global licensing deal with Novavax for access to its Matrix M vaccine adjuvant technology.
The agreement allows Pfizer to use Matrix M in vaccines for up to two infectious diseases, with upfront, milestone, and royalty payments involved.
Pfizer shares most recently closed at $25.52, with the stock showing a 32.1% decline over the past 3 years and a 12.7% decline over 5 years. Against that backdrop, this licensing move adds a fresh element to the...